Progyny (NASDAQ:PGNY) Issues Q1 2025 Earnings Guidance

Progyny (NASDAQ:PGNY) updated its first quarter 2025 earnings guidance on Thursday. The company provided earnings per share guidance of 0.440-0.470 for the period, compared to the consensus earnings per share estimate of 0.400. The company issued revenue guidance of $300.0 million-$318.0 million, compared to the consensus revenue estimate of $280.5 million. Progyny also updated its FY 2025 guidance to 1.520-1.620 EPS.

Wall Street Analysts Forecast Growth

PGNY has been the subject of several research analyst reports. Truist Financial reaffirmed a “hold” rating and issued a $19.00 price objective (down previously from $26.00) on shares of Progyny in a report on Wednesday, November 13th. Bank of America raised their target price on Progyny from $21.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, February 11th. Canaccord Genuity Group decreased their price target on Progyny from $18.00 to $17.00 and set a “hold” rating on the stock in a report on Wednesday, November 13th. Barclays dropped their price objective on Progyny from $30.00 to $17.00 and set an “overweight” rating for the company in a research note on Thursday, November 14th. Finally, JPMorgan Chase & Co. lifted their target price on Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a research note on Tuesday, January 28th. Nine analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $25.83.

Progyny Stock Down 0.5 %

PGNY traded down $0.12 on Thursday, hitting $22.88. The company had a trading volume of 2,306,329 shares, compared to its average volume of 1,776,190. The company has a market cap of $1.95 billion, a PE ratio of 39.45, a PEG ratio of 2.39 and a beta of 1.34. The business’s fifty day simple moving average is $20.34 and its 200 day simple moving average is $18.65. Progyny has a 12-month low of $13.39 and a 12-month high of $38.98.

Insider Activity

In other Progyny news, Chairman David J. Schlanger bought 150,000 shares of the business’s stock in a transaction dated Thursday, December 26th. The shares were purchased at an average price of $14.68 per share, with a total value of $2,202,000.00. Following the completion of the purchase, the chairman now owns 228,269 shares in the company, valued at $3,350,988.92. This represents a 191.65 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Peter Anevski purchased 209,500 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The shares were acquired at an average cost of $14.48 per share, with a total value of $3,033,560.00. Following the completion of the purchase, the chief executive officer now directly owns 441,463 shares in the company, valued at $6,392,384.24. The trade was a 90.32 % increase in their position. The disclosure for this purchase can be found here. Insiders own 12.30% of the company’s stock.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.